PBPK – a bridge between in silico, in vitro and in vivo to advance your drug discovery project
6 May 2015
In drug discovery there is a growing need to predict human pharmacokinetics as early as possible, and for this physiologically based pharmacokinetic (PBPK) modelling is a valuable approach acknowledged also by the regulatory authorities. At Admescope, we are using GastroPlusTM, a widely used software package among pharmaceutical companies.
PBPK modelling can be utilised throughout the drug discovery and development process1. In the early phases it can be used to integrate available in vitro and in silico data to predict in vivo PK profiles, potentially reducing the number of animal studies needed. Furthermore, it can be used to guide the experimental work needed to complete the understanding of discrepancies between PBPK predictions and in vivo PK observations. PBPK is an advantageous tool also in the lead selection, enabling the early selection of the best candidates and projection of First-in-Human PK profiles.
In addition, PBPK can be carried on using in clinical phases to predict the outcomes in patient populations when human in vivo data with healthy volunteers is available or making drug-drug interaction (DDI) simulations and many more applications.
Contact us if you would like to learn how our expertise with PBPK could help you advancing your drug discovery projects!
1. Jones H, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247-262.
